Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

It’s going to be an experiment to go off of it.” As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...

Zepbound, at a fraction of the branded cost, but with little known about their efficacy or safety. Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy ...

The drug tirzepatide ... is used primarily for diabetes treatment but like its sibling Zepbound has also been approved for ...

Eli Lilly is exploring the possibility of expanding its weight-loss drugs Mounjaro and Zepbound beyond just obese patients. The company is considering testing these medications on people who aren ...

Eli Lilly announced that it is suing three different companies for selling products claiming to contain tirzepatide, the main ingredient in its weight-loss drug Zepbound. The companies include ...